Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Patent metadata

Field	Value
Publication number	US-10029984-B2
Application number	US-201615542735-A
Country	US
Kind code	B2
Filing date	Jan 15, 2016
Priority date	Jan 16, 2015
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

First claim

The invention claimed is:

1. A compound of formula (I)

wherein:
R 1 is F, R 2 is F, CH 3 or OCH 3 and R 3 is H,
R 1 is H, R 2 is Cl or F and R 3 is CH 3 ,
R 1 is CH 3 , R 2 is OCH 3 , F or H and R 3 =H,
R 1 is H, R 2 is Cl or F and R 3 is H,
R 1 is CH 3 , R 2 is H and R 3 is F,
R 1 is F, R 2 is H and R 3 is CH 3 ,
R 1 is H, R 2 is OCH 3 and R 3 is H or Cl,
R 1 is H, R 2 is F and R 3 is F,
R 1 is CF 3 or OCF 3 , R 2 is H and R 3 is H,
R 1 is Cl, R 2 is OCH 3 and R 3 is H;
and a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.

2. A compound of claim 1 selected from the group consisting of:

and a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.

3. A pharmaceutical composition comprising a compound of claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A method of inhibiting the replication of dengue virus in a biological sample or patient, comprising administering to said sample or patient a dengue virus replication-inhibiting amount of the compound of claim 1 .

5. The method of claim 4 , further comprising administering an additional therapeutic agent.

Assignees

• Janssen Pharmaceuticals Inc
• Univ Leuven Kath

Inventors

• Kesteleyn Bart Rudolf Romanie
• Bonfanti Jean-François
• Jonckers Tim Hugo Maria
• Raboisson Pierre Jean-Marie Bernard
• Bardiot Dorothée Alice Marie-Eve
• Marchand Arnaud Didier M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• C07D209/14 Primary

  Radicals substituted by nitrogen atoms, not forming part of a nitro radical · CPC title

• A61K31/4045 Primary

  Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin · CPC title